Published on October 28, 2009 at 10:26 AM
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, has received approval from the New England Institutional Review Board (IRB) to enroll the first patient in a Phase II clinical trial of cervical dysplasia (cervical intraepithelial neoplasia or CIN).
The study will be a blinded, randomized comparison of ADXS11-001 versus placebo for the treatment of cervical dysplasia.
SOURCE Advaxis, Inc.,